Email Updates

Search form

You are here

16 AUGUST 2019 VOLUME 20 ISSUE 31

Media Coverage

  • The global health community got a few pieces of hopeful news this week. On Monday the World Health Organization announced that two newly developed intravenous drug therapies appear capable of curing Ebola. Then, on Wednesday, the Food and Drug Administration effectively endorsed a three-drug treatment that appears to cure so-called extensively drug-resistant tuberculosis — the deadliest version of the world’s deadliest infectious disease. Together, these developments could mark a pivotal moment in the century-long quest for global health security.

    August 16, 2019
    General
    New York Times
  • In 1966, a 38-year-old man visited a hospital in what is now the Democratic Republic of Congo. His name, his symptoms, and everything about him beyond his age and gender have been lost to history. But a piece of one of his lymph nodes was collected and preserved. By analyzing it, a team of researchers led by Michael Worobey from the University of Arizona have shown that the man was infected by HIV, the virus that causes AIDS. He wouldn’t have known it, though, and nor would his doctors. HIV was formally discovered 17 years later.

    August 16, 2019
    General
    The Atlantic
  • Kenyan women on long-acting contraceptives recorded higher rates of sexually transmitted infections, compared to the general population, a new study reveals.

    August 15, 2019
    Daily Nation
  • Zimbabwe has just started a national roll-out of the new antiretroviral drug, Dolutegravir (DTG), which is set to gradually wean off Tenolam E.

    August 14, 2019
    All Africa
  • The third in an annual series of UK surveys conducted by Public Health England in collaboration with PrEPster and iwantPrEPnow (IWPN) reports that although the proportion of people who have ever used HIV pre-exposure prophylaxis (PrEP) has not increased since the previous survey, a higher proportion report currently using PrEP.

    August 14, 2019
    aidsmap
  • Delays in rolling out an HIV prevention pill in Britain are putting gay men’s lives at risk, with thousands buying it online without medical supervision, HIV campaigners said on Wednesday.

    August 14, 2019
    Reuters
  • Even as the science around HIV treatment and prevention moves forward at a brisk pace, much of the public image around the disease and who’s at risk remains static. That problem is exacerbated by clinical studies for HIV drugs that don’t accurately reflect the populations that need them.

    August 14, 2019
    Bloomberg Law
  • Nelly Mugo, MB ChB, from the Kenya Medical Research Institute and the University of Washington in Seattle, was counseling a woman about her recent HIV diagnosis when the patient caught her off guard. "I came to you guys 2 years ago and had a baby," she recalls her patient saying. Mugo's colleagues at the maternity wing of an urban hospital in Nairobi helped deliver the woman's baby. "I was negative. Nobody told me that I was at risk for getting HIV."

    August 14, 2019
    Medscape
  • When she joined a trial of new tuberculosis drugs, the dying young woman weighed just 57 pounds. Stricken with a deadly strain of the disease, she was mortally terrified. Local nurses told her the Johannesburg hospital to which she must be transferred was very far away — and infested with vervet monkeys.

    August 14, 2019
    General
    New York Times
  • Winnie Byanyima will soon take the helm of UNAIDS as its new executive director, it was announced Wednesday, concluding a months-long selection process to find a new leader for the embattled agency.

    August 14, 2019
    General
    Devex
  • HIV Vaccine and Advocacy Society, NHVMAS, has urged the Federal government to embrace a policy change on adolescents’ age of access to Sexual Reproductive Health, SRH and HIV services to 14 years. The Society who made the call during a media roundtable on ‘adolescents’ sexual reproductive health and age of consent said policy change would ensure that the age of maturity at 18 years will not constitute a barrier in accessing services.

    August 13, 2019
    General
    Vanguard
  • California lawmakers are working to make PrEP and PEP available as over-the-counter drugs without a prescription, reports Capital Public Radio. The legislation would authorize pharmacists to provide PrEP and PEP without a prescription, much like birth control pills are currently available in the Golden State.

    August 12, 2019
    Instinct Magazine
  • A preclinical trial of a tenofovir disoproxil fumarate (TDF) intravaginal ring for HIV pre-exposure prophylaxis ended early after 8 of 12 women unexpectedly developed vaginal ulcers.

    August 12, 2019
    Contagion Live
  • A vaccine to protect against chlamydia has moved closer to becoming reality after a pioneering clinical trial found the treatment to be safe. The vaccine successfully provoked an immune response, boosting levels of antibodies against the chlamydia bacterium in the blood and vaginal fluids.

    August 12, 2019
    General
    The Guardian
  • Financial incentives to remain in school reduced HIV incidence among adolescent girls and young women in eSwatini (Swaziland) by 21 percent, and participants exposed to both financial incentives and a lottery open only to those who remained free of sexually transmitted infections (STIs) were 37 percent less likely to acquire HIV infection, a trial has found.

    August 12, 2019
    General
    aidsmap
  • Since the introduction of azidothymidine in 1987 there have been major improvements in the treatment of HIV. In a recently published study, Forsythe and colleagues demonstrate that the advent of antiretroviral therapy (ART) in the mid 1990s has yielded significant achievements in global public health. Between 1995 and 2015, 9.5 million deaths have been averted worldwide, and global economic benefits are estimated at over $1 trillion.

    August 12, 2019
    General
    Forbes
  • In a development that transforms the fight against Ebola, two experimental treatments are working so well that they will now be offered to all patients in the Democratic Republic of Congo, scientists announced on Monday.

    August 12, 2019
    General
    New York Times
  • Among all the CAR-T commotion you may have missed it: An FDA panel on Wednesday recommended Gilead’s Descovy to block HIV transmission in men and transgender women, a step toward another PrEP finally coming to market (the sole medicine right now being Gilead’s Truvada). One potential snag — the advisory committee narrowly voted not to recommend the medicine, which is already approved to treat HIV, for women who are not transgender, also referred to as cisgender women.

    August 9, 2019
    Politico
  • Gilead Sciences Inc.'s donation of enough of its drug Truvada to treat 200,000 people for 10 years comes with some concerns for community health centers that say that it, and funding in President Donald Trump’s HIV plan, could do more harm than good if not distributed properly.

    August 9, 2019
    Bloomberg Law

Published Research

Announcements